Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/178638
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSáinz Jaspeado, Miguel Guillermo-
dc.contributor.authorMartín Liberal, Juan Jesús-
dc.contributor.authorLagares Tena, Laura-
dc.contributor.authorMateo Lozano, Silvia-
dc.contributor.authorGarcía del Muro Solans, Xavier-
dc.contributor.authorTirado, Oscar M.-
dc.date.accessioned2021-06-23T14:37:22Z-
dc.date.available2021-06-23T14:37:22Z-
dc.date.issued2011-04-01-
dc.identifier.issn1949-2553-
dc.identifier.urihttp://hdl.handle.net/2445/178638-
dc.description.abstractSarcomas represent a heterogeneous group of tumors with a complex and difficult reproducible classification. Their pathogenesis is poorly understood and there are few effective treatment options for advanced disease. Caveolin-1 is a multifunctional scaffolding protein with multiple binding partners that regulates multiple cancer-associated processes including cellular transformation, tumor growth, cell death and survival, multidrug resistance, angiogenesis, cell migration and metastasis. However, ambiguous roles have been ascribed to caveolin-1 in signal transduction and cancer, including sarcomas. In particular, evidence indicating that caveolin-1 function is cell context dependent has been repeatedly reported. Caveolin-1 appears to act as a tumor suppressor protein at early stages of cancer progression. In contrast, a growing body of evidence indicates that caveolin-1 is up-regulated in several multidrug-resistant and metastatic cancer cell lines and human tumor specimens. This review is focused on the role of caveolin-1 in several soft tissue and bone sarcomas and discusses the use of this protein as a potential diagnostic and prognostic marker and as a therapeutic target.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherImpact Journals-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.18632/oncotarget.255-
dc.relation.ispartofOncotarget, 2011, vol. 2, num. 4, p. 305-312-
dc.relation.urihttps://doi.org/10.18632/oncotarget.255-
dc.rightscc-by (c) Sáinz Jaspeado, Miguel Guillermo et al., 2011-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subject.classificationFisiologia-
dc.subject.classificationSarcoma-
dc.subject.classificationDiagnòstic-
dc.subject.classificationEtiologia-
dc.subject.otherPhysiology-
dc.subject.otherSarcoma-
dc.subject.otherDiagnosis-
dc.subject.otherEtiology-
dc.titleCaveolin-1 in sarcomas: friend or foe?-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec680008-
dc.date.updated2021-06-23T14:37:22Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid21471610-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
680008.pdf1.08 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons